Patidegib
Information
- Drug Name
- Patidegib
- Description
- Entry(CIViC)
- 1
CIViC
| Disease | Mutation | EL | ET | ED | CS | VO | TR | Pubmed | Links |
|---|---|---|---|---|---|---|---|---|---|
| Brain Medulloblastoma |
SMO p.Asp473His (p.D473H) ( ENST00000249373.8 ) SMO p.Asp473His (p.D473H) ( ENST00000249373.8 ) |
D |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 3 | 22550175 | Detail |
Annotation
| Description | Associated Genes | Associated Variants | Sensitivity | Supported | Source | Links |
|---|---|---|---|---|---|---|
| Saridegib treatment induced tumor reduction and si... | SMO |
SMO p.Asp473His (p.D473H) ( ENST00000249373.8 ) SMO p.Asp473His (p.D473H) ( ENST00000249373.8 ) |
Sensitivity | true | CIViC Evidence | detail |
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT02762084 | Completed | Phase 2 | Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas in Gorlin Syndrome Patients | June 6, 2016 | April 24, 2017 |
| NCT02828111 | Completed | Phase 2 | Clinical Trial of Patidegib Gel 2%, 4%, and Vehicle Applied Once or Twice Daily to Decrease the GLI1 Biomarker in Sporadic Nodular Basal Cell Carcinomas | November 11, 2016 | November 9, 2017 |